Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, according to a late-breaking presentation at the American Academy of Dermatology ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting showed that the candidate, icotrokinra (JNJ-2113), was associated with ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Under the agreement terms, Alumis will receive $40 million in upfront and near-term co-development payments, with the possibility of an additional $140 million in milestone and field option payments.